Compare · PLUR vs RVMD
PLUR vs RVMD
Side-by-side comparison of Pluri Inc. (PLUR) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PLUR and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $38.35B, about 1953.0x PLUR ($19.6M).
- Over the past year, PLUR is down 65.8% and RVMD is up 369.1% - RVMD leads by 434.9 points.
- PLUR has been more active in the news (5 items in the past 4 weeks vs 3 for RVMD).
- RVMD has more recent analyst coverage (25 ratings vs 0 for PLUR).
- Company
- Pluri Inc.
- Revolution Medicines Inc.
- Price
- $1.91+2.42%
- $180.18-3.20%
- Market cap
- $19.6M
- $38.35B
- 1M return
- -15.71%
- +14.14%
- 1Y return
- -65.80%
- +369.10%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- News (4w)
- 5
- 3
- Recent ratings
- 0
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest PLUR
- Pluri Inc. filed SEC Form 8-K: Other Events
- Pluri Chairman Alejandro Weinstein’s Cumulative Investment Exceeds $17 Million, Ownership Surpasses 30%
- Pluri Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- New insider Shorrer Doron claimed ownership of 13,628 shares (SEC Form 3)
- Director Manieu Alexandre Weinstein was granted 641 shares, increasing direct ownership by 10% to 6,925 units (SEC Form 4)
- Pluri Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing
- Pluri Inc. filed SEC Form 8-K: Other Events
- SEC Form 10-Q filed by Pluri Inc.
- Director Manieu Alexandre Weinstein was granted 625,000 shares (SEC Form 4)
Latest RVMD
- European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
- Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Patel Sushil exercised 2,955 shares at a strike of $37.54 and sold $1,048,967 worth of shares (5,580 units at $187.99) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 21,656 units (SEC Form 4)
- Chief Financial Officer Anders Jack exercised 20,000 shares at a strike of $18.56 and sold $3,366,604 worth of shares (20,000 units at $168.33) as part of a pre-agreed trading plan (SEC Form 4)
- Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
- Director Kim Lorence H. was granted 1,191 shares, increasing direct ownership by 2% to 74,281 units (SEC Form 4)
- Director Borisy Alexis was granted 1,191 shares, increasing direct ownership by 0.05% to 2,340,075 units (SEC Form 4)
- Director Anderson Elizabeth M was granted 1,191 shares, increasing direct ownership by 14% to 9,406 units (SEC Form 4)
- Director Horning Sandra was granted 1,191 shares, increasing direct ownership by 1% to 97,765 units (SEC Form 4)
- Director Clyburn Frank was granted 1,191 shares, increasing direct ownership by 12% to 10,929 units (SEC Form 4)